Helicobacter pylori: the place of the new macrolides in the eradication of the bacteria in peptic ulcer disease.
Burette
A
A
Gastroenterology Unit, Nouvelle Clinique de la Basilique, Brussels, Belgium.
Glupczynski
Y
Y
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001729:Bismuth / Q000627:therapeutic use; D017291:Clarithromycin / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D005260:Female; D005757:Gastritis, Atrophic / Q000188:drug therapy*; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D009853:Omeprazole / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome; D014475:Uncoupling Agents / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D014475:Uncoupling Agents; D017291:Clarithromycin; D009853:Omeprazole; D001729:Bismuth